Seoul: Samsung Biologics Co. has announced a remarkable first-quarter net profit of 375.6 billion won (US$263.9 million), marking a 109.4 percent increase from the previous year. The company's financial performance was disclosed in a regulatory filing on Wednesday, highlighting substantial growth in both operating profit and revenue.
According to Yonhap News Agency, Samsung Biologics reported an operating profit of 486.7 billion won for the quarter, a significant rise from 221.3 billion won in the same period last year. Revenue also showed considerable growth, increasing by 37.1 percent to reach 1.29 trillion won. These figures surpassed market expectations, as analysts had estimated an average net profit of 313 billion won, based on a survey conducted by Yonhap Infomax, the financial data firm of Yonhap News Agency.
The notable financial results underscore Samsung Biologics' strong market performance and operational efficiency in the first quarter. The company's ability to exceed analyst predictions reflects its robust strategic planning and execution in the competitive biopharmaceutical industry.